Bimatoprost as a Treatment for Graves' Orbitopathy

Part of paid clinical trials in Seattle, Washington.

Sponsor
Johns Hopkins University
Study ID
NCT03708627
Phase
EARLY_PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Graves Ophthalmopathy

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Bimatoprost Ophthalmic — DRUG
    Bimatoprost, aka Lumigan, one drop in one eye nightly

Study Details

Testing whether Bimatoprost, a topical eye drop used for glaucoma, can be used to induce periorbital fat atrophy in patients with Graves' disease

Key Dates

Start date
Nov 1, 2017
Status verified
Jul 2025
Primary completion
Jul 1, 2029
Completion
Jul 1, 2031

Study Design

Enrollment
3 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Bimatoprost in more proptotic eye
    Patients instill Bimatoprost in their more proptotic eye one nightly
  • No Intervention: Control
    Bimatoprost is not instilled in the patient's fellow eye

Primary Outcome Measure

Reduction in periorbital fat causing improvement in proptosis [ Time Frame: 1 year ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of WashingtonSeattleWashington98104
Alexandra Van Brummen, MD
[email protected]
206-543-7250

Find similar trials in Seattle, WA

By research site
University of Washington· Seattle, WA

Related Studies